AC
BOLD

Ascend Capital’s Audentes Therapeutics, Inc BOLD Stock Holding History

Ascend Capital’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-92,576
Closed -$2.89M – 293
2017
Q4 		$2.89M Sell
92,576
-59,210
-39% -$1.63M 0.11% 155
2017
Q3 		$4.25M Buy
+151,786
New +$3.3M 0.16% 112

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ascend Capital's BOLD Position: Q1 2018 in Review

Ascend Capital sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2018, closing a stake of 92,576 shares — an estimated $2.89M sold.

Ascend Capital first reported a position in BOLD in Q3 2017 and held it in 2 quarters. The position peaked at $4.25M in Q3 2017. 114 funds tracked by Wall St. Rank hold BOLD as of Q1 2018.

  • Ascend Capital reported no remaining Audentes Therapeutics, Inc position as of Q1 2018 after selling out during the quarter.
  • Ascend Capital sold 92,576 Audentes Therapeutics, Inc shares in Q1 2018, an estimated $2.89M.
  • Ascend Capital first reported a position in Audentes Therapeutics, Inc in Q3 2017 and held it in 2 quarters.
  • Ascend Capital's Audentes Therapeutics, Inc position peaked at $4.25M in Q3 2017.
  • 114 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.